
    
      This study consists of 2 parts: Part 1 is a single ascending dose study where subjects will
      receive either ASP3700 or matching placebo; Part 2 is a drug-drug interaction (DDI)
      open-label, crossover study comprised of 1 sequence with 2 investigational periods where
      subjects will receive ASP3700 alone and in combination with itraconazole.
    
  